Company / EPS (Diluted)
Catalyst Pharmaceuticals Partners, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$1.68
FY2025
5-year range
$0.37 / $1.68
FY2021-FY2025
Trend
+28.2%
vs FY2024
Sector context
#28 of 204
Health Care
What the data says
Catalyst Pharmaceuticals Partners, Inc.'s eps (diluted) of $1.68 is higher than 86% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-0.33 in FY2020 to $1.68 in FY2025.
Based on SEC 10-K filings.
1.68 in FY2025 with a 3-year CAGR of +30.8%. Top quartile in the Health Care sector.
Improved from $0.63 to $1.68 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- +30.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
+228.9% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 28.2% year-over-year.
- Ranks #28 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 4.78 (safe zone, above 2.9 threshold)
- Strong profit margin: 33.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.68 | +28.2% |
| FY2024 | $1.31 | +107.9% |
| FY2023 | $0.63 | -16.0% |
| FY2022 | $0.75 | +102.7% |
| FY2021 | $0.37 | +212.1% |
| FY2020 | -$0.33 | +0.0% |
| FY2019 | -$0.33 | -57.1% |
| FY2018 | -$0.21 | +16.0% |
| FY2017 | -$0.25 | -13.6% |
| FY2016 | -$0.22 | +12.0% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026